JPMorgan analyst Tessa Romero initiated coverage of EyePoint Pharmaceuticals with an Overweight rating and $35 price target. The analyst sees EyePoint as offering a pipeline of indications within a single product built around its approach to sustained delivery via an intravitreal injection with EYP-190. In the lead indication of wet age-related macular degeneration which afflicts at least 1.5M patients in the U.S. alone, EyePoint has recently showcased Phase 2 data that suggest it can possibly be a six-month maintenance treatment option as a new mechanism of action in the paradigm, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EYPT:
- EyePoint director sells $37.2M in common stock
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint price target lowered to $33 from $35 at H.C. Wainwright
- Insider Trading: EyePoint Stock (NASDAQ:EYPT) Up on Major Insider Buy